Compare Adaptive Biotechnologies Corp (ADPT) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Payoneer Global Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Payoneer Global Inc trades at $7.09 (market cap $2.40B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap. Which is the better fit depends on your goals.
| ADPT | PAYO | |
|---|---|---|
Market Cap | $3.33B | $2.40B |
Sector | Health | Technology |
52-Week High | $22.37 | $7.42 |
52-Week Low | $10.24 | $4.27 |
Enterprise Value | $3.19B | $2.14B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Payoneer Global (PAYO) trades at $7.10, up slightly by 0.14% today, with a bullish technical signal from moving averages and a consensus analyst price target of $8.20. Recent financials show revenue growth to $821.16 million in 2025, though net income declined to $73.19 million, and the company is the subject of a pending $2.75 billion acquisition by Nuvei announced in June 2026.
The acquisition offer at $7.40 per share, below the consensus target, creates uncertainty but provides a near-term floor. Risks include integration challenges and shareholder litigation over deal fairness, while fundamentals like a 79.4% gross margin and positive cash flow support long-term value if the deal falls through.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
